Hyaline membrane surfactant prophylaxis in the preterm baboon: A comparison of postpartum versus in utero therapy

H. L. Galan, C. Cipriani, J. J. Coalson, J. D. Bean-Lijewski, G. Collier, T. J. Kuehl

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Intra-amniotic administration of surfactant (IAS) in the preterm baboon 24 h before delivery reduces the clinical and pathological aspects of hyaline membrane disease (HMD) when compared to saline controls. The purpose of this study is to describe clinical, radiographical, and pathological endpoints of HMD in the preterm baboon treated with a single intratracheal dose of surfactant (ITS) for comparison with those of IAS and intra-amniotic saline-treated control groups. Methods: Five preterm baboons received control intra-amniotic saline injections before delivery and ITS (4 ml/kg Survanta, Ross Laboratories, Cincinnati, Ohio) following delivery. An additional saline-treated baboon was delivered but not given surfactant. Fetuses were delivered at 137-139 days' gestation, maintained for 24 h using standard neonatal intensive care techniques and assessed for study endpoints. These data were compared to those from our previous report to assess differences between intratracheal and intra-amniotic administration of surfactant and controls. Results: Compared to saline controls, ITS- and IAS-treated animals had significantly better clinical courses, as documented by PaO2/PAO2 (p < 0.05), FiO2 (p < 0.01), and PaCO2 (p < 0.05). Saline controls had significantly more evidence of HMD than intra-amniotic and intratracheal surfactant-treated animals in blindly scored radiographs (p < 0.03). Using a panel-of-standards method blindly to score pathological findings in the fixed left lung, those treated with intra-amniotic and intratracheal surfactant had significantly more inflation (p < 0.05) than saline-treated animals. ITS- and IAS-treated animals had no differences in study endpoints. Animals receiving intratracheal surfactant tended to have residual inflation in the central and medial aspects of each lobe, in contrast to intra-amniotic surfactant-treated animals which had a more even distribution of inflation. Conclusion: Intratracheal surfactant treatment improves the clinical, radiographical and pathological aspects of respiratory distress in the preterm baboon, but does not prevent hyaline membrane disease in this established model. Variations in distribution of inflation between intratracheal and intra-amniotic surfactant-treated animals suggest differences in pulmonary distribution of surfactant that depend on the route of administration.

Original languageEnglish (US)
Pages (from-to)122-130
Number of pages9
JournalPrenatal and Neonatal Medicine
Volume1
Issue number2
StatePublished - 1996

Fingerprint

Hyalin
Papio
Surface-Active Agents
Postpartum Period
Membranes
Hyaline Membrane Disease
Economic Inflation
Therapeutics
Neonatal Intensive Care
Pulmonary Surfactants

Keywords

  • Baboon
  • Hyaline membrane disease
  • In utero therapy
  • Pregnancy
  • Preterm delivery
  • Surfactant prophylaxis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Galan, H. L., Cipriani, C., Coalson, J. J., Bean-Lijewski, J. D., Collier, G., & Kuehl, T. J. (1996). Hyaline membrane surfactant prophylaxis in the preterm baboon: A comparison of postpartum versus in utero therapy. Prenatal and Neonatal Medicine, 1(2), 122-130.

Hyaline membrane surfactant prophylaxis in the preterm baboon : A comparison of postpartum versus in utero therapy. / Galan, H. L.; Cipriani, C.; Coalson, J. J.; Bean-Lijewski, J. D.; Collier, G.; Kuehl, T. J.

In: Prenatal and Neonatal Medicine, Vol. 1, No. 2, 1996, p. 122-130.

Research output: Contribution to journalArticle

Galan, HL, Cipriani, C, Coalson, JJ, Bean-Lijewski, JD, Collier, G & Kuehl, TJ 1996, 'Hyaline membrane surfactant prophylaxis in the preterm baboon: A comparison of postpartum versus in utero therapy' Prenatal and Neonatal Medicine, vol. 1, no. 2, pp. 122-130.
Galan, H. L. ; Cipriani, C. ; Coalson, J. J. ; Bean-Lijewski, J. D. ; Collier, G. ; Kuehl, T. J. / Hyaline membrane surfactant prophylaxis in the preterm baboon : A comparison of postpartum versus in utero therapy. In: Prenatal and Neonatal Medicine. 1996 ; Vol. 1, No. 2. pp. 122-130.
@article{11747acf49254a9f907abcb21472926e,
title = "Hyaline membrane surfactant prophylaxis in the preterm baboon: A comparison of postpartum versus in utero therapy",
abstract = "Objective: Intra-amniotic administration of surfactant (IAS) in the preterm baboon 24 h before delivery reduces the clinical and pathological aspects of hyaline membrane disease (HMD) when compared to saline controls. The purpose of this study is to describe clinical, radiographical, and pathological endpoints of HMD in the preterm baboon treated with a single intratracheal dose of surfactant (ITS) for comparison with those of IAS and intra-amniotic saline-treated control groups. Methods: Five preterm baboons received control intra-amniotic saline injections before delivery and ITS (4 ml/kg Survanta, Ross Laboratories, Cincinnati, Ohio) following delivery. An additional saline-treated baboon was delivered but not given surfactant. Fetuses were delivered at 137-139 days' gestation, maintained for 24 h using standard neonatal intensive care techniques and assessed for study endpoints. These data were compared to those from our previous report to assess differences between intratracheal and intra-amniotic administration of surfactant and controls. Results: Compared to saline controls, ITS- and IAS-treated animals had significantly better clinical courses, as documented by PaO2/PAO2 (p < 0.05), FiO2 (p < 0.01), and PaCO2 (p < 0.05). Saline controls had significantly more evidence of HMD than intra-amniotic and intratracheal surfactant-treated animals in blindly scored radiographs (p < 0.03). Using a panel-of-standards method blindly to score pathological findings in the fixed left lung, those treated with intra-amniotic and intratracheal surfactant had significantly more inflation (p < 0.05) than saline-treated animals. ITS- and IAS-treated animals had no differences in study endpoints. Animals receiving intratracheal surfactant tended to have residual inflation in the central and medial aspects of each lobe, in contrast to intra-amniotic surfactant-treated animals which had a more even distribution of inflation. Conclusion: Intratracheal surfactant treatment improves the clinical, radiographical and pathological aspects of respiratory distress in the preterm baboon, but does not prevent hyaline membrane disease in this established model. Variations in distribution of inflation between intratracheal and intra-amniotic surfactant-treated animals suggest differences in pulmonary distribution of surfactant that depend on the route of administration.",
keywords = "Baboon, Hyaline membrane disease, In utero therapy, Pregnancy, Preterm delivery, Surfactant prophylaxis",
author = "Galan, {H. L.} and C. Cipriani and Coalson, {J. J.} and Bean-Lijewski, {J. D.} and G. Collier and Kuehl, {T. J.}",
year = "1996",
language = "English (US)",
volume = "1",
pages = "122--130",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Hyaline membrane surfactant prophylaxis in the preterm baboon

T2 - A comparison of postpartum versus in utero therapy

AU - Galan, H. L.

AU - Cipriani, C.

AU - Coalson, J. J.

AU - Bean-Lijewski, J. D.

AU - Collier, G.

AU - Kuehl, T. J.

PY - 1996

Y1 - 1996

N2 - Objective: Intra-amniotic administration of surfactant (IAS) in the preterm baboon 24 h before delivery reduces the clinical and pathological aspects of hyaline membrane disease (HMD) when compared to saline controls. The purpose of this study is to describe clinical, radiographical, and pathological endpoints of HMD in the preterm baboon treated with a single intratracheal dose of surfactant (ITS) for comparison with those of IAS and intra-amniotic saline-treated control groups. Methods: Five preterm baboons received control intra-amniotic saline injections before delivery and ITS (4 ml/kg Survanta, Ross Laboratories, Cincinnati, Ohio) following delivery. An additional saline-treated baboon was delivered but not given surfactant. Fetuses were delivered at 137-139 days' gestation, maintained for 24 h using standard neonatal intensive care techniques and assessed for study endpoints. These data were compared to those from our previous report to assess differences between intratracheal and intra-amniotic administration of surfactant and controls. Results: Compared to saline controls, ITS- and IAS-treated animals had significantly better clinical courses, as documented by PaO2/PAO2 (p < 0.05), FiO2 (p < 0.01), and PaCO2 (p < 0.05). Saline controls had significantly more evidence of HMD than intra-amniotic and intratracheal surfactant-treated animals in blindly scored radiographs (p < 0.03). Using a panel-of-standards method blindly to score pathological findings in the fixed left lung, those treated with intra-amniotic and intratracheal surfactant had significantly more inflation (p < 0.05) than saline-treated animals. ITS- and IAS-treated animals had no differences in study endpoints. Animals receiving intratracheal surfactant tended to have residual inflation in the central and medial aspects of each lobe, in contrast to intra-amniotic surfactant-treated animals which had a more even distribution of inflation. Conclusion: Intratracheal surfactant treatment improves the clinical, radiographical and pathological aspects of respiratory distress in the preterm baboon, but does not prevent hyaline membrane disease in this established model. Variations in distribution of inflation between intratracheal and intra-amniotic surfactant-treated animals suggest differences in pulmonary distribution of surfactant that depend on the route of administration.

AB - Objective: Intra-amniotic administration of surfactant (IAS) in the preterm baboon 24 h before delivery reduces the clinical and pathological aspects of hyaline membrane disease (HMD) when compared to saline controls. The purpose of this study is to describe clinical, radiographical, and pathological endpoints of HMD in the preterm baboon treated with a single intratracheal dose of surfactant (ITS) for comparison with those of IAS and intra-amniotic saline-treated control groups. Methods: Five preterm baboons received control intra-amniotic saline injections before delivery and ITS (4 ml/kg Survanta, Ross Laboratories, Cincinnati, Ohio) following delivery. An additional saline-treated baboon was delivered but not given surfactant. Fetuses were delivered at 137-139 days' gestation, maintained for 24 h using standard neonatal intensive care techniques and assessed for study endpoints. These data were compared to those from our previous report to assess differences between intratracheal and intra-amniotic administration of surfactant and controls. Results: Compared to saline controls, ITS- and IAS-treated animals had significantly better clinical courses, as documented by PaO2/PAO2 (p < 0.05), FiO2 (p < 0.01), and PaCO2 (p < 0.05). Saline controls had significantly more evidence of HMD than intra-amniotic and intratracheal surfactant-treated animals in blindly scored radiographs (p < 0.03). Using a panel-of-standards method blindly to score pathological findings in the fixed left lung, those treated with intra-amniotic and intratracheal surfactant had significantly more inflation (p < 0.05) than saline-treated animals. ITS- and IAS-treated animals had no differences in study endpoints. Animals receiving intratracheal surfactant tended to have residual inflation in the central and medial aspects of each lobe, in contrast to intra-amniotic surfactant-treated animals which had a more even distribution of inflation. Conclusion: Intratracheal surfactant treatment improves the clinical, radiographical and pathological aspects of respiratory distress in the preterm baboon, but does not prevent hyaline membrane disease in this established model. Variations in distribution of inflation between intratracheal and intra-amniotic surfactant-treated animals suggest differences in pulmonary distribution of surfactant that depend on the route of administration.

KW - Baboon

KW - Hyaline membrane disease

KW - In utero therapy

KW - Pregnancy

KW - Preterm delivery

KW - Surfactant prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=0011328304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0011328304&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 122

EP - 130

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 2

ER -